Genoveffa Franchini - Vaccines

Author Information

Genoveffa Franchini is a prominent researcher affiliated with the Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research at the National Cancer Institute in Bethesda, MD, USA. Her work primarily focuses on the development of vaccines and the study of viral infections, particularly related to HIV and HTLV-1. She has made significant contributions to understanding the immunological mechanisms underlying vaccine efficacy and viral pathogenesis.

Research Contributions

Genoveffa Franchini has an extensive research portfolio that spans various aspects of immunology and virology. Her work has provided invaluable insights into the modulation of immune responses during primary HTLV-1 infection, the mechanisms driving immunogenicity in HIV vaccines, and the role of antibody-dependent cellular phagocytosis in vaccine-induced protection. Her research also explores the genetic and functional aspects of viral proteins and their implications in disease progression. Notably, she has contributed to the understanding of how vaccine regimens can alter microbiomes and influence immune responses in non-human primate models.

Aliases

Throughout her career, Genoveffa Franchini has been recognized by several aliases, including G Franchini and G. Franchini. These variations are commonly found in academic publications and databases.

Publication and Citation Metrics

Metric	Value
Total Citation Count	18,410
H-Index	74
Total Number of Papers	422

Publications:

NK cells and monocytes modulate primary HTLV-1 infection

DOI: 10.1371/journal.ppat.1010416

Year: 2022

The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination

DOI: 10.1038/s41590-021-01026-9

Year: 2021

Decision letter: Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1

DOI: 10.7554/elife.69577.sa1

Year: 2021

Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates

DOI: 10.1016/j.isci.2021.102047

Year: 2021

Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases

DOI: 10.1186/s12943-021-01370-2

Year: 2021

A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques

DOI: 10.1128/JVI.01225-20

Year: 2020

Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques

DOI: 10.1128/JVI.01933-19

Year: 2020

The V2 loop of HIV gp120 delivers costimulatory signals to CD4+ T cells through Integrin α4β7 and promotes cellular activation and infection.

DOI: 10.1073/pnas.2011501117

Year: 2020

Functional properties and sequence variation of HTLV-1 p13

DOI: 10.1186/s12977-020-00517-1

Year: 2020

Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition

DOI: 10.1371/journal.ppat.1008377

Year: 2020

Are There Any Contraindications for Newborn Vaccination?

What is Clinical Immunization Safety Assessment (CISA)?

Which Vaccines are Recommended?

How Can Public Awareness Improve Hygiene Practices?

Do Vaccines Cause the Diseases They Are Meant to Prevent?

What is Influenza?

How Do Vaccines Boost the Immune System?

What is Oseltamivir?

How Can Vaccines Cause Paralysis?

What is the CISA Project?

Partnered Content Networks

Relevant Topics